Core Viewpoint - enCore Energy Corp. plans to offer $75 million in convertible senior notes due 2030, with an option for initial purchasers to buy an additional $11.25 million [1][2] Group 1: Offering Details - The convertible notes will be senior unsecured obligations, bearing interest payable semi-annually, maturing on August 15, 2030 [2] - Holders can convert their notes under certain conditions, with settlement options including cash, common shares, or a combination [2] - The company may redeem the notes for cash starting August 21, 2028, if the common share price exceeds 130% of the conversion price for a specified period [2] Group 2: Use of Proceeds - A portion of the net proceeds will be used for capped call transactions related to the convertible notes [3] - Remaining proceeds will be allocated to repay outstanding amounts under a loan agreement and for general corporate purposes [3] Group 3: Capped Call Transactions - Capped call transactions are expected to reduce potential dilution of common shares upon conversion of the notes [5] - These transactions will be privately negotiated with financial institutions and are subject to anti-dilution adjustments [4] Group 4: Market Impact - The option counterparties may engage in derivative transactions and purchase common shares, potentially affecting the market price of enCore's shares and the convertible notes [6][7] - This activity could influence the holders' ability to convert the notes and the cash or shares received upon conversion [8] Group 5: Company Overview - enCore Energy Corp. is focused on providing clean, reliable, and affordable fuel for nuclear energy, being the only U.S. uranium company with multiple Central Processing Plants in operation [10] - The company utilizes in-situ recovery (ISR) for uranium extraction, a proven technology co-developed by its leadership [10] - Future projects include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming [11]

Core Viewpoint - A class action securities lawsuit has been filed against Tesla, Inc. alleging securities fraud that affected investors between April 19, 2023, and June 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Tesla overstated the effectiveness of its autonomous driving technology [2] - It is alleged that there was a significant risk that Tesla's autonomous vehicles, including the Robotaxi, would operate dangerously or violate traffic laws [2] - The lawsuit suggests that these issues increased the likelihood of heightened regulatory scrutiny on Tesla [2] - Consequently, Tesla's business and financial prospects were allegedly overstated, making public statements materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 3, 2025, to request to be appointed as lead plaintiff [2] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [2][3] Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Neogen Corporation is facing a class action securities lawsuit due to alleged securities fraud that misled investors regarding the integration with 3M Company's Food Safety Division [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by misleading statements made between January 5, 2023, and June 3, 2025 [1]. - Defendants allegedly issued materially false statements about the integration's progress and downplayed inefficiencies that arose during the process [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2]. - It is alleged that this situation created a substantial risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submi ...

Core Viewpoint - A class action securities lawsuit has been filed against KinderCare Learning Companies, Inc. due to alleged securities fraud affecting investors who purchased shares during the October 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to KinderCare Learning Companies, Inc. [2] - The complaint alleges that KinderCare concealed numerous incidents of child abuse, neglect, and harm at its facilities, failing to provide the highest quality care and meet minimum industry standards [3]. - As a result of these issues, KinderCare is said to be exposed to undisclosed risks including lawsuits, regulatory actions, negative publicity, reputational damage, and business loss [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until October 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States [5].

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sable Offshore Corp. ("Sable Offshore Corp." or the "Company") (NYSE: SOC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sable Offshore Corp. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June ...

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for bipolar disorder [2]. - It is alleged that the misleading statements were likely to have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated, leading to materially false and misleading public statements [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].